Subsequent Events	6 Months Ended
Feb. 28, 2013
Subsequent Events [Abstract]
Subsequent Events	Note 6: Subsequent Events On January 11, 2013 the company signed a non-binding Letter of Intent with Glycomar Limited of Oban, Scotland. The letter provides that Rosewind will undertake a $3,000,000 fundraising to furnish cash for continuation of Glycomar's drug development program. Upon completion of this funding Rosewind will issue 20,000,000 shares of its common stock to acquire all outstanding shares of Glycomar Limited. More information on Glycomar Limited is available at www.glycomar.com. The Company has evaluated all other subsequent events through the date that the financial statements were issued, per the requirements of ASC Topic 855, and has determined that there are no additional events to report.

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

No definition available.

Name:	us-gaap_SubsequentEventsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration